Industry Sponsored Clinical Trials
- Study of ocrelizumab in patients <65 years old with primary or secondary progressive MS (Opening Soon!)
- Randomized, placebo controlled trial of MEDI-551 (inebilizumab) for highly active neuromyelitis optica (Clinicaltrials.gov Identifier NCT02200770)
- Study of how ocrelizumab changes immune cells in the spinal fluid (Clinicaltrials.gov Identifier NCT02688985)
- Study of high dose biotin for progressive MS (Clinicaltrials.gov Identifier NCT02936037) (Closed to enrollment)
Please contact Sheila Florin at MSresearch@yale.edu for additional information.
The Chairman of the Yale Department of Neurology is world-renowned Professor David A. Hafler, MD. Dr. Hafler’s research has greatly advanced the understanding of the function of the immune system in MS, of the relationship of MS to other autoimmune diseases, and the genetic underpinnings of MS in relation to autoimmune diseases. Researchers in Dr. Hafler’s lab are exploring the role of dietary salt and body fat in multiple sclerosis, exploring the gut microbiome in multiple sclerosis, and performing cutting-edge research about MS genetics. Newly diagnosed MS patients are invited to contribute to this research by donating blood, stool, fat tissue, and/or spinal fluid.
For more information about Dr. Hafler's work, see his laboratory website.
One root cause for MS-related disability is neurodegeneration, yet the cause for this neurodegeneration is not well understood. Dr. David Pitt’s research is aimed at better understanding this phenomenon. His lab is studying the impact of genetic risk factors on inflammation and neurodegeneration in the brain and spinal cord.
For more information about Dr. Pitt’s work, see his laboratory website.
While it has become clear that B-cells play an important role in MS, many of the details regarding exactly how they contribute remain to be discovered. Dr. Kevin O’Connor’s laboratory works to define the mechanisms by which B-cells, and the antibodies they produce, cause tissue damage in MS, neuromyelitis optica (NMO) and other autoimmune diseases.
For more information about Dr. O’Connor’s work, see his laboratory website.